Skip to main content

Zacks Analyst Interview Highlights: BioMarin, Regeneron, Onyxx Pharma, 3SBio and AMAG Pharma

Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Grant Zeng, who discusses BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), Onyx Pharmaceuticals Inc. (Nasdaq: ONXX), 3SBio Inc. (Nasdaq: SSRX), and AMAG Pharmaceuticals Inc. (Nasdaq: AMAG).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2678.

Based on our belief that this time the biotech industry is more negatively affected by the current credit crunch rather than the economic slowdown, we do see opportunities existing for some biotech companies. In this broad, undifferentiated, beaten-down market, we believe companies with less financing pressure may benefit from the recovery of the broad market.

Specifically, companies with strong balance sheet and low cash burn rate, and/or with approved products on the market, will survive amid the current bleak economic conditions. At this point, “cash is king” is the single most important factor to evaluate a biotech company, especially for smaller ones.

With the above criteria in mind, our top picks for the biotech industry are BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), Onyx Pharmaceuticals Inc. (Nasdaq: ONXX), 3SBio Inc. (Nasdaq: SSRX), and AMAG Pharmaceuticals Inc. (Nasdaq: AMAG).

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks Profit from the Pros e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contacts:

Zacks.com
Mark Vickery
Zacks Web Content Editor
312-265-9380
Visit: www.zacks.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.